FDA Approved: REZVOGLAR KWIKPEN — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

The FDA approved a supplemental application for Rezvoglar KwikPen (insulin glargine-AGLR) from Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rezvoglar KwikPen (INSULIN GLARGINE-AGLR)

Snippet

SUPPL AP for REZVOGLAR KWIKPEN (INSULIN GLARGINE-AGLR)